CENTREVILLE, Va., April 3, 2025 /PRNewswire/ -- CARFAX, a leader in vehicle history and valuation, announced today the enhancement of its Total Loss Valuation Report to include automated calculation of taxes and fees. This enhancement is made possible through a partnership with Claim Toolkit, offering claims professionals the ability to more efficiently and accurately incorporate taxes and fees into final settlement amounts. Since its launch in 2020, CARFAX's Total Loss Valuation Report has been extensively adopted by insurance companies across the United States, providing mor

NEW YORK, April 2, 2025 /PRNewswire/ -- S&P Global's (NYSE: SPGI) first quarter 2025 results will be issued on Tuesday, April 29, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on April 29, 2025 to discuss the Company's first quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck, and any additio

Annual survey reveals increasing retail investor access and GenAI playing a larger role in investment workflows NEW YORK, April 1, 2025 /PRNewswire/ -- The private equity and venture capital industries are optimistic as deal activity and fundraising is improving, despite caution about the macroeconomic environment, according to the S&P Global Market Intelligence 2025 Private Equity and Venture Capital Outlook. According to the annual survey, 71% of general partners (GPs) are more optimistic about the private equity deal environment than they were a year ago, with 67% of ventu

Mizuho initiated coverage of S&P Global with a rating of Outperform and set a new price target of $599.00

Citigroup initiated coverage of S&P Global with a rating of Buy and set a new price target of $600.00

Goldman initiated coverage of Protagonist Therapeutics with a rating of Neutral and set a new price target of $47.00

4 - S&P Global Inc. (0000064040) (Issuer)

4 - S&P Global Inc. (0000064040) (Issuer)

4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

DEFA14A - S&P Global Inc. (0000064040) (Filer)

DEF 14A - S&P Global Inc. (0000064040) (Filer)

8-K - Protagonist Therapeutics, Inc (0001377121) (Filer)

NEW YORK, March 26, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, and S&P SmallCap 600: Cava Group Inc. (NYSE:CAVA) will replace Altair Engineering Inc. (NASD: ALTR) in the S&P MidCap 400 effective prior to the opening of trading on Monday, March 31. Siemens AG (XETR: SIE) acquired Altair Engineering in a deal completed today.Angi Inc. (NASD: ANGI) will replace The ODP Corp. (NASD: ODP) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, April 2. S&P SmallCap 600 constituent IAC Inc. (NASD: IAC) is spinning off its ownership interest in ANGI in a transaction expected to be completed on Tuesday, April 1. Post spi

NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

NEW YORK, March 4, 2025 /PRNewswire/ -- Albertsons Companies Inc. (NYSE:ACI) will replace Aspen Technology Inc. (NASD: AZPN) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, March 11. S&P 500 constituent Emerson Electric Co. (NYSE:EMR) is acquiring Aspen Technology in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date  Index Name         Action  Company Name  Ticker  GICS Sector  March 11, 2025   S&P MidCap 400   Addition   Albertsons Companies ACI   Consumer Staples   March 11, 2025   S&P MidCap 400   Del

NEW YORK, April 2, 2025 /PRNewswire/ -- S&P Global's (NYSE: SPGI) first quarter 2025 results will be issued on Tuesday, April 29, 2025 via news release at approximately 7:15 a.m. Eastern Daylight Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations, will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time on April 29, 2025 to discuss the Company's first quarter 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, supplemental deck, and any additio

S&P 500 Q4 2024 buybacks were $243.2 billion, up 7.4% from Q3 2024's $226.6 billion and up 11.0% from Q4 2023's $219.1 billionThe 2024 expenditure set an annual record of $942.5 billion and was up 18.5% from the 2023 expenditure of $795.2 billion Consumer Staples increased spending by 97.9% as Financials and Communication Services reduced their spending by 4.4% and 14.0%, respectively The net buyback 1% tax reduced Q4 2024 operating earnings by 0.37% and As Reported GAAP by 0.39%, as the year is 0.44% and 0.50%, respectivelyNEW YORK, March 19, 2025 /PRNewswire/ -- S&P Dow Jones Indices (S&P DJI) today announced the preliminary S&P 500® stock buybacks or share repurchases data for Q4 2024. Hi

− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)